Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC)

Authors :: Stephen J. Gwyther
Kim Benstead
Ian Chau
Matthew T. Seymour
Tamas Hickish
S Falk
Sarah Brown
Susan D. Richman
Catherine Olivier
Gary Middleton
Nick Wadd
Alfred Oliver
Philip Quirke
Ann O'Callaghan
L K Dawson
Philip A. Chambers
Tim Maughan
Jonathan Wadsley
Vicky Napp
H Marshall
Source :: Journal of Clinical Oncology. 29:3523-3523
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 3523 Background: Phase III trials show inconsistent effects when anti-EGFR drugs are added to cytotoxic therapy in aCRC. Benefits, when present, are confined to patients (pts) determined retrospect...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Phase iii trials
business.industry
Pharmacology
humanities
law.invention
Irinotecan
Advanced colorectal cancer
Randomized controlled trial
law
Internal medicine
medicine
Panitumumab
Cytotoxic Therapy
business
medicine.drug

Full Text Access

Tools